Gossamer Bio Inc (GOSS) Given Consensus Recommendation of “Strong Buy” by Analysts

Shares of Gossamer Bio Inc (NASDAQ:GOSS) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the four brokers that cover the stock, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy recommendation.

Brokerages have set a twelve-month consensus target price of $29.25 for the company and are anticipating that the company will post ($0.77) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Gossamer Bio an industry rank of 77 out of 255 based on the ratings given to its competitors.

Several equities analysts have issued reports on the company. Svb Leerink assumed coverage on Gossamer Bio in a research report on Tuesday, March 5th. They issued an “outperform” rating and a $30.00 price objective for the company. Barclays assumed coverage on Gossamer Bio in a research report on Tuesday, March 5th. They issued an “overweight” rating and a $27.00 price objective for the company. Evercore ISI assumed coverage on Gossamer Bio in a research report on Tuesday, March 5th. They issued an “outperform” rating and a $30.00 price objective for the company. Bank of America assumed coverage on Gossamer Bio in a research report on Tuesday, March 5th. They issued a “buy” rating and a $30.00 price objective for the company. Finally, Leerink Swann assumed coverage on Gossamer Bio in a research report on Tuesday, March 5th. They issued an “outperform” rating for the company.

In other Gossamer Bio news, CFO Bryan Giraudo bought 6,000 shares of the firm’s stock in a transaction on Tuesday, February 12th. The stock was purchased at an average cost of $16.00 per share, with a total value of $96,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Russell J. Cox bought 7,200 shares of the firm’s stock in a transaction on Tuesday, February 12th. The stock was acquired at an average cost of $16.00 per share, with a total value of $115,200.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 14,750 shares of company stock valued at $236,000.

Shares of Gossamer Bio stock traded up $0.45 during midday trading on Thursday, hitting $20.00. 253,500 shares of the company were exchanged, compared to its average volume of 472,383. Gossamer Bio has a 52 week low of $16.00 and a 52 week high of $25.06.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist that is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma, as well as that has completed Phase I clinical trial for chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticarial; GB002, a platelet-derived growth factor, receptor kinase inhibitor that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension; GB004, an oral small molecule that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and GB1275, an oral small molecule for the treatment of oncology indications.

Read More: Roth IRA

Get a free copy of the Zacks research report on Gossamer Bio (GOSS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Gossamer Bio (NASDAQ:GOSS)

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply